Pregabalin Capsule
Product Images NDC 60760-485

Product Visual Gallery

This gallery contains 14 technical images submitted to the FDA as part of the official labeling for Pregabalin (NDC 60760-485). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by St. Mary's Medical Park Pharmacy, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Preg (Pregabalin 60760 485 60)

Pregabalin Capsules 75 mg label for oral capsules in a quantity of 60. The label includes storage instructions to keep at controlled room temperature between 15°-30°C (59°-86°F) and states 'Use as directed' and 'Rx only.' Manufactured by ScieGen Pharmaceuticals, Inc. and packaged by St. Mary's Medical Park Pharmacy in Oro Valley, AZ. The label shows product NDC 60760-485-60.*

FDA Label Image

Figure 1 (Pregabalin Fig01)

A line graph showing the percent of patients improved versus percent improvement in pain from baseline for Pregabalin oral capsules. The graph compares four groups: Pregabalin 25 mg three times a day, 100 mg three times a day, 200 mg three times a day, and placebo, illustrating improvement trends across increasing doses of Pregabalin.*

FDA Label Image

Figure 2 (Pregabalin Fig02)

A line graph comparing percent improvement in pain from baseline on the x-axis with percent of patients improved on the y-axis. It shows two data series, one for Pregabalin 100 mg three times a day and one for placebo. The Pregabalin line consistently shows a higher percentage of patient improvement across the range compared to placebo.*

FDA Label Image

Figure 3 (Pregabalin Fig03)

A line graph showing the percent of patients improved versus percent improvement in pain from baseline for Pregabalin at doses of 75 mg, 150 mg, and 300 mg taken twice a day, compared to placebo. The graph illustrates dose-dependent increases in patient improvement.*

FDA Label Image

Figure 4 (Pregabalin Fig04)

A line graph comparing the percent of patients improved by percent improvement in pain from baseline for Pregabalin 200 mg three times a day, Pregabalin 100 mg three times a day, and placebo. The vertical axis shows percent of patients improved, and the horizontal axis shows percent improvement in pain ranging from 0 to 100.*

FDA Label Image

Figure 5 (Pregabalin Fig05)

A line graph depicting the percent of patients improved by percent improvement in pain from baseline. The graph compares three groups: Pregabalin 100 mg three times a day, Pregabalin 50 mg three times a day, and placebo. Percent improvement ranges from just above 0 to 100 along the horizontal axis, while the vertical axis shows percent of patients improved from 0 to 100.*

FDA Label Image

Figure 6 (Pregabalin Fig06)

This is a bar chart showing responder rates (%) from two clinical studies labeled Study E1 and Study E3. The vertical axis shows responder rates from 0% to 60%, and the horizontal axis lists treatment groups with placebo and various dosages (mg/day) of a drug. Statistically significant differences versus placebo are indicated by asterisks for certain dosage groups in both studies.*

FDA Label Image

Figure 7 (Pregabalin Fig07)

A line graph showing seizure reduction as median percent change from baseline versus dose in mg/day. The graph compares four studies (E1 BD, E2 TID, E3 BD, E3 TID) with different dosing regimens, displaying data points and significant p-values indicating statistical significance of seizure reduction at various doses, including placebo at zero dose.*

FDA Label Image

Figure 9 (Pregabalin Fig08)

A line graph showing percent improvement in pain from baseline on the x-axis and percent of patients improved on the y-axis. The graph compares four groups: Pregabalin 800 mg daily dose, Pregabalin 450 mg daily dose, Pregabalin 300 mg daily dose, and placebo, illustrating trends in patient improvement across different dosage levels.*

FDA Label Image

Figure 10 (Pregabalin Fig09)

A line graph comparing the estimated percentage of subjects without LTR over a period of 180 days for Pregabalin versus Placebo. The vertical axis shows percentage from 0% to 100%, and the horizontal axis represents days. The Pregabalin group maintains a higher percentage of subjects without LTR throughout the study period compared to Placebo.*

FDA Label Image

Figure 11 (Pregabalin Fig10)

A line graph comparing the percent of subjects improved from baseline to week 12 BOCF for Pregabalin versus placebo. The x-axis shows percent improvement from 0 to 100, and the y-axis shows percent of subjects improved. Pregabalin is represented by a solid line, showing higher improvement percentages across the range compared to the placebo, represented by a dashed line.*

FDA Label Image

Figure 12 (Pregabalin Fig11)

A line graph comparing the percent of subjects improved from baseline to week 16 using the BOCF method for Pregabalin versus Placebo. The x-axis represents the percent improvement ranging from 0 to 100%, and the y-axis shows the cumulative percent of subjects improved, from 0 to 100. The graph features two lines: a solid line for Pregabalin and a dotted line for Placebo, illustrating higher improvement rates for Pregabalin across the improvement percentages.*

FDA Label Image

Cockcroft And Gault Equation (Pregabalin Formula)

Mathematical formula for creatinine clearance (CLcr) calculation displayed. The formula uses age in years, weight in kilograms, and serum creatinine in mg/dL, with an adjustment factor of 0.85 for female patients. This formula appears to support clinical calculations related to drug dosing or kidney function assessment.*

FDA Label Image

Chemical Structure (Pregabalin Str)

Chemical structure of the active ingredient Pregabalin, showing its molecular arrangement with functional groups including amino and carboxy groups.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.